A groundbreaking clinical trial for a new pancreatic cancer vaccine has been launched in Birmingham, making a patient the first in Europe to participate. The vaccine, developed by BioNTech and Genentech, is personalized for each individual and aims to train the immune system to combat cancer cells, potentially reducing the risk of cancer recurrence after surgery. Meanwhile, researchers at Oxford University are working on a vaccine for Lynch syndrome, a genetic condition that significantly increases the risk of several cancers, including bowel and womb cancers. The project, named LynchVax, seeks to teach the immune system to identify and destroy pre-cancerous cells, with the potential to improve survival rates. Lynch syndrome affects approximately one in 400 people in England, but awareness of the condition remains low, with only 5% of those affected knowing they have it. Both initiatives highlight promising advancements in cancer prevention and treatment.